Fresenius Medical Care : Q3 2018 results: No surprises after recent profit warning
>Q3 2018 results: Weakness in all three segments - In Q3 2018 FME delivered 3% group revenue growth on a comparable basis and group EBIT growth of 5% (+4% at cc). Reported EBIT was down -13% due to one offs. The figures included no surprises given the recent profit warning. The detailed segment breakdown showed that the weakness extended across all businesses. On a comparable basis, Health Care Services revenue increased 3% yoy, mainly driven by organic growth in...RegistrarFresenius Medical Care is a kidney dialysis company, operating in both the field of dialysis services and the field of dialysis products for the treatment of end-stage renal disease (ESRD). Co.'s dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. In addition, Co. sells dialysis products to other dialysis service providers. In the U.S.A., Co. also provides inpatient dialysis services and other services under contract to hospitals. Co. provides patient services, including renal pharmaceutical products and in the U.S.A., laboratory services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.